Osteoporozda Medikal Tedavi ve Yeni Seçenekler

Yıl 2019, Cilt: 11 Sayı: 3, 108 - 113, 03.05.2019

Tuğba Aydın

Öz

Osteoporoz kemik kırılganlığında artış ile karekterize oldukça yaygın kas iskelet sistemi
hastalığıdır. Tedavide amaç; kırıkların önlenmesi, kemik mineral yoğunluğunun artırılması,
kırıklara bağlı deformitelerin azaltılması ve yaşam kalitesinin yükseltilmesidir.
Osteoporoz tedavisinde kullanılan birçok ilaç vardır. Önemli olan doğru hastada ideal
ilaçı secmektir.

Anahtar Kelimeler

osteoporoz , medikal tedavi , medikal

Kaynakça

• 1. Eskiyurt N. Osteoporozdan korunma; genel önlemler (kalsiyum, d vitamini ve fiziksel aktivite). Turkiye Klinikleri J PM&RSpecial Topics 2012;5(3):98-103
• 2. Lindsay R., Cosman F. Osteoporosis . In Kasper DL., Fauci AS., Hauser S. Et al. Harrison’s Principles of Internal Medicine. 19th ed. 2016 2488-2504
• 3. Tuzun S, Eskiyurt N, Akarırmak U, Sarıdoğan M, Şenocak ( Turkish Osteoporosis Society) Incidence of hip fractue and prevalance of osteoporosis in Turkey: the FRACTURK study. Osteoporos Int 2012;23(3) :949-55
• 4. Sözen T, Özışık L, Başaran NÇ. An overview and management of osteoporosis. Eur J Rheumatol. 2017 Mar;4(1):46-56. doi: 10.5152/eurjrheum.2016.048. Epub 2016 Dec 30.
• 5. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R; Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014 Oct;25(10):2359-81.
• 6. Compston J, Cooper A0, Cooper C, Gittoes N, Gregson C, Harvey N, Hope S, Kanis JA, McCloskey EV, Poole KES, Reid DM, Selby P, Thompson F, Thurston A, Vine N; National Osteoporosis Guideline Group (NOGG). UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017 Dec;12(1):43
• 7. Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS, Pessah-Pollack R, Tangpricha V, Wimalawansa SJ, Watts NB. Amerıcan Assocıatıon Of Clınıcal Endocrınologısts And Amerıcan College Of Endocrınology Clınıcal Practıce Guıdelınes For The Dıagnosıs And Treatment Of Postmenopausal Osteoporosıs - 2016. Endocr Pract. 2016 Sep 2;22(Suppl 4):1-42.
• 8. Gamze Kılıç, Salih Özgöçmen. Osteoporozda Medikal Tedavi Turkiye Klinikleri J PM&R-Special Topics 2012;5(3):104-18
• 9. O'Connor KM. Evaluation and Treatment of Osteoporosis. Med Clin North Am. 2016 Jul;100(4):807-26. doi: 10.1016/j.mcna.2016.03.016
• 10. Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, Compston JE, Drake MT, Edwards BJ, Favus MJ, Greenspan SL, McKinney R Jr, Pignolo RJ, Sellmeyer DE. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016 Jan;31(1):16-35
• 11. Osteoporoz ve metabolik kemik hastalıkları tanı ve tedavi klavuzu 2016, Türkiye Endokrinoloji ve Metabolizma Derneği 12. Costa AG, Bilezikian JP. How Long to Treat with Denosumab. Curr Osteoporos Rep. 2015 Dec;13(6):415-20. Review.
• 13. Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guañabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC. Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone. 2017 Aug 5;105:11-17
• 14. Scaglione M, Fabbri L, Casella F, Guido G. Strontium ranelate as an adjuvant for fracture healing: clinical, radiological, and ultrasound findings in a randomized controlled study on wrist fractures. Osteoporos Int. 2016 Jan;27(1):211-8
• 15. Silva GA, Bertassoli BM, Sousa CA, Albergaria JD, de Paula RS, Jorge EC. Effects of strontium ranelate treatment on osteoblasts cultivated onto scaffolds of trabeculae bovine bone. J Bone Miner Metab. 2017 Mar 20.
• 16.Wells G, Chernoff J, Gilligan JP, Krause DS. Does salmon calcitonin cause cancer? A review and meta-analysis. Osteoporos Int. 2016 Jan;27(1):13-9.
• 17. Sindel D. Günümüzde ve Gelecekte osteoporoz tedavisi. Türk Fiz Tıp Rehab Derg 2013;59:330-7
• 18. Abdelazim IA, Abdelrazak KM, Al-Kadi M, Yehia AH, Nusair BM, Faza MA. Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis. Arch Osteoporos. 2014;9:189
• 19. Gonnelli S, Caffarelli C. Abaloparatide. Clin Cases Miner Bone Metab. 2016 May-Aug;13(2):106-109
• 20. Chew CK, Clarke BL. Abaloparatide: Recombinant human PTHrP (1-34) anabolic therapy for osteoporosis. Maturitas. 2017 Mar;97:53-60
• 21. FDA approves Radius Health's TYMLOS™ (abaloparatide), a bone building agent for the treatment of postmenopausal women with osteoporosis at high risk for fracture [press release].Waltham,MA Radius Health. http://investors.radiuspharm.com/releasedetail.cfm?ReleaseID= 1023557. Published April 28, 2017. Accessed May 9, 2017.
• 22. Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, Dokoupilova E, Engelke K, Finkelstein JS, Genant HK, Goemaere S, Hyldstrup L, Jodar-Gimeno E, Keaveny TM, Kendler D, Lakatos P, Maddox J, Malouf J, Massari FE, Molina JF, Ulla MR, Grauer A. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017 Jul 26. pii: S0140-6736(17)31613-6.
• 23. Ishibashi H, Crittenden DB, Miyauchi A, Libanati C, Maddox J, Fan M, Chen L, Grauer A. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study. Bone. 2017 Oct;103:209-215
• 24. de Villiers TJ. The quest for new drugs to prevent osteoporosis- related fractures. Climacteric. 2017 Apr;20(2):103-106